Published in Mol Cancer Ther on April 06, 2010
Anticancer Activity of Nicotinamide on Lung Cancer | NCT02416739
SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell (2011) 2.73
Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol (2011) 2.23
Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone Spine (2013) 2.06
Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer (2013) 2.02
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal muscle fiber types. Proc Natl Acad Sci U S A (2010) 1.71
Sorting out functions of sirtuins in cancer. Oncogene (2013) 1.47
Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci (2012) 1.43
ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther (2011) 1.32
Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. Cell Cycle (2012) 1.27
SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS One (2012) 1.27
Peptide switch is essential for Sirt1 deacetylase activity. Mol Cell (2011) 1.26
Sirtuin activators and inhibitors. Biofactors (2012) 1.19
A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med (2012) 1.18
Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J (2014) 1.12
Protein post-translational modifications and regulation of pluripotency in human stem cells. Cell Res (2013) 1.12
MicroRNA-138 and SIRT1 form a mutual negative feedback loop to regulate mammalian axon regeneration. Genes Dev (2013) 1.11
The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene (2012) 1.11
The ways and means that fine tune Sirt1 activity. Trends Biochem Sci (2013) 1.07
The Roles of SIRT1 in Cancer. Genes Cancer (2013) 1.04
The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica (2011) 1.03
Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol (2011) 1.03
Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des (2013) 1.01
Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.01
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS One (2012) 1.00
Age-related susceptibility to apoptosis in human retinal pigment epithelial cells is triggered by disruption of p53-Mdm2 association. Invest Ophthalmol Vis Sci (2012) 0.99
Sirtuin inhibitors as anticancer agents. Future Med Chem (2014) 0.98
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model. Arthritis Rheum (2013) 0.94
A redox-resistant sirtuin-1 mutant protects against hepatic metabolic and oxidant stress. J Biol Chem (2014) 0.93
The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer (2013) 0.92
A nutrient-sensitive interaction between Sirt1 and HNF-1α regulates Crp expression. Aging Cell (2011) 0.91
Poly(ADP-ribose) polymerase-1-induced NAD(+) depletion promotes nuclear factor-κB transcriptional activity by preventing p65 de-acetylation. Biochim Biophys Acta (2013) 0.90
Depletion of the central metabolite NAD leads to oncosis-mediated cell death. J Biol Chem (2014) 0.90
Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J Pharmacol Exp Ther (2014) 0.90
Histone/protein deacetylase SIRT1 is an anticancer therapeutic target. Am J Cancer Res (2014) 0.90
SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis. Transl Cancer Res (2012) 0.90
A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem (2013) 0.89
Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis (2013) 0.88
Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal (2014) 0.88
Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation. PLoS One (2014) 0.88
Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. Sci Rep (2015) 0.88
Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep (2016) 0.86
Resveratrol (trans-3,5,4'-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-κB. Mol Nutr Food Res (2011) 0.86
SIRT1 activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease. Acta Neuropathol Commun (2014) 0.86
Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target. Lab Invest (2015) 0.84
The expression and correlation of SIRT1 and Phospho-SIRT1 in colorectal cancer. Int J Clin Exp Med (2015) 0.84
Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance. Curr Drug Targets (2016) 0.84
Apurinic/apyrimidinic endonuclease 1 is a key modulator of aluminum-induced neuroinflammation. BMC Neurosci (2013) 0.84
Resveratrol Induced Premature Senescence Is Associated with DNA Damage Mediated SIRT1 and SIRT2 Down-Regulation. PLoS One (2015) 0.84
Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. PLoS One (2012) 0.84
SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. Cell Death Dis (2015) 0.83
SIRT1 inhibits the mouse intestinal motility and epithelial proliferation. Am J Physiol Gastrointest Liver Physiol (2011) 0.83
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia (2012) 0.82
The Deacetylase Sirtuin 1 Regulates Human Papillomavirus Replication by Modulating Histone Acetylation and Recruitment of DNA Damage Factors NBS1 and Rad51 to Viral Genomes. PLoS Pathog (2015) 0.82
Utilisation of nanoparticle technology in cancer chemoresistance. J Drug Deliv (2012) 0.81
Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem (2014) 0.81
The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci (2013) 0.80
Profiling deacetylase activities in cell lysates with peptide arrays and SAMDI mass spectrometry. Anal Chem (2013) 0.80
Resveratrol differentially regulates NAMPT and SIRT1 in Hepatocarcinoma cells and primary human hepatocytes. PLoS One (2014) 0.80
Spinal SIRT1 activation attenuates neuropathic pain in mice. PLoS One (2014) 0.80
Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. Cancer Sci (2014) 0.80
Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Sci Rep (2014) 0.79
SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner. Neuro Oncol (2014) 0.79
The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors. Medchemcomm (2012) 0.79
Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets. Viruses (2014) 0.79
Association of SIRT1 and HMGA1 expression in non-small cell lung cancer. Oncol Lett (2015) 0.78
Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis. Cancer Biol Ther (2015) 0.78
Evaluation of benzoic acid derivatives as sirtuin inhibitors. Bioorg Med Chem Lett (2013) 0.78
Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. Oncotarget (2015) 0.78
Acute Treatment of Resveratrol Alleviates Doxorubicin-Induced Myotoxicity in Aged Skeletal Muscle Through SIRT1-Dependent Mechanisms. J Gerontol A Biol Sci Med Sci (2015) 0.77
Loss of BRG1 induces CRC cell senescence by regulating p53/p21 pathway. Cell Death Dis (2017) 0.77
Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob/ob mice. Acta Pharmacol Sin (2015) 0.77
A potent and selective small molecule inhibitor of sirtuin 1 promotes differentiation of pluripotent P19 cells into functional neurons. Sci Rep (2016) 0.77
Cell cycle-dependent changes in H3K56ac in human cells. Cell Cycle (2015) 0.76
Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines. Int J Prev Med (2013) 0.76
Insight into the Mechanism of Intramolecular Inhibition of the Catalytic Activity of Sirtuin 2 (SIRT2). PLoS One (2015) 0.76
RhoA Ambivalently Controls Prominent Myofibroblast Characteritics by Involving Distinct Signaling Routes. PLoS One (2015) 0.76
MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1. J Immunol (2015) 0.76
A Label-free Sirtuin 1 Assay based on Droplet-Electrospray Ionization Mass Spectrometry. Anal Methods (2016) 0.75
Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL). Cancer Biol Ther (2016) 0.75
Human Sirtuin 2 Localization, Transient Interactions, and Impact on the Proteome Point to Its Role in Intracellular Trafficking. Mol Cell Proteomics (2016) 0.75
Suppression of silent information regulator 1 activity in noncancerous tissues of hepatocellular carcinoma: Possible association with non-B non-C hepatitis pathogenesis. Cancer Sci (2015) 0.75
SIRT1 increases YAP- and MKK3-dependent p38 phosphorylation in mouse liver and human hepatocellular carcinoma. Oncotarget (2016) 0.75
82-kDa choline acetyltransferase and SATB1 localize to β-amyloid induced matrix attachment regions. Sci Rep (2016) 0.75
Sirtuin inhibitor sirtinol is an intracellular iron chelator. Chem Commun (Camb) (2015) 0.75
SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Oncotarget (2016) 0.75
Expression of the SIRT2 gene and its relationship with body size traits in Qinchuan cattle (Bos taurus). Int J Mol Sci (2015) 0.75
Role of SIRT1-mediated mitochondrial and Akt pathways in glioblastoma cell death induced by Cotinus coggygria flavonoid nanoliposomes. Int J Nanomedicine (2015) 0.75
SIRT1 is a critical regulator of K562 cell growth, survival, and differentiation. Exp Cell Res (2016) 0.75
Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding. Int J Biol Sci (2016) 0.75
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget (2017) 0.75
Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther (2017) 0.75
The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer (2007) 8.05
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Triple-negative breast cancer: therapeutic options. Lancet Oncol (2007) 4.80
Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer (2002) 4.57
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood (2004) 4.03
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem (2003) 3.41
Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol (2002) 3.20
FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol (2002) 2.86
Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol (2002) 2.84
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol (2006) 2.57
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol (2010) 2.51
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 2.35
Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res (2009) 2.32
FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta (2011) 2.32
The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A (2009) 2.29
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med (2008) 2.27
Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther (2008) 2.18
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res (2006) 2.13
Crystal structure of pea Toc34, a novel GTPase of the chloroplast protein translocon. Nat Struct Biol (2002) 2.02
Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol (2009) 1.99
Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res (2005) 1.99
Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab (2004) 1.97
Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol (2007) 1.96
FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res (2010) 1.95
Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation (2007) 1.83
The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem (2006) 1.68
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res (2011) 1.64
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol (2004) 1.63
T:G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha. J Biol Chem (2003) 1.62
Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 1.62
Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene (2002) 1.62
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther (2009) 1.56
Crystal structure of Get4-Get5 complex and its interactions with Sgt2, Get3, and Ydj1. J Biol Chem (2010) 1.54
Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium. Mol Endocrinol (2005) 1.51
Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol (2006) 1.49
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol (2009) 1.46
Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol (2007) 1.45
Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther (2008) 1.44
Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res (2005) 1.42
The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium. Endocrinology (2008) 1.42
FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J Biol Chem (2006) 1.40
Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One (2010) 1.40
Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene (2003) 1.39
Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Res (2007) 1.38
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol (2013) 1.38
Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol Endocrinol (2006) 1.37
Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res (2007) 1.35
LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat (2011) 1.33
Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. Proc Natl Acad Sci U S A (2006) 1.32
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res (2011) 1.32
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol (2011) 1.31
The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol (2008) 1.31
Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res (2007) 1.29
Crystal structures of the 70-kDa heat shock proteins in domain disjoining conformation. J Biol Chem (2008) 1.29
The transcription factor encyclopedia. Genome Biol (2012) 1.28
A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer (2009) 1.27
Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res (2004) 1.26
Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle (2008) 1.25
Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem (2011) 1.23
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther (2007) 1.21
Commitment point during G0-->G1 that controls entry into the cell cycle. Mol Cell Biol (2003) 1.21
miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res (2013) 1.21
H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem (2002) 1.21
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res (2006) 1.19
Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer (2006) 1.18
Crystal structure of the C-terminal 10-kDa subdomain of Hsc70. J Biol Chem (2003) 1.17
FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets (2011) 1.17
Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene (2004) 1.16
Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim Biophys Acta (2012) 1.16
Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J Mol Endocrinol (2008) 1.15
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica (2010) 1.14